Phase 3 pivotal program in MESI – PEAK and PINNACLE Study Design PEAK PINNACLE Primary endpoint BCVA change from baseline to the average of Week 20 and 24 Key secondary endpoint Proportion of patients in whom BCVA had improved by ≥15 letters from baseline to 24 weeks Weeks D1 4 8 12 16 20 24 28 32 36 40 44 48 KSI-101 5 mg KSI-101 10 mg Sham Primary endpoint KSI-101 5 mg injection Sham injection KSI-101 10 mg injection Individualized treatment (PRN) Sham PRN Fixed monthly dosing Individualized dosing 90 PEAK and PINNACLE are actively enrolling